Literature DB >> 21971605

Diagnostic accuracy of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in differentiated thyroid cancer patients with elevated thyroglobulin and negative (131)I whole body scan: evaluation by thyroglobulin level.

Sae Jung Na1, Ie Ryung Yoo, Joo Hyun O, Chenghe Lin, Qiuyu Lin, Sung Hoon Kim, Soo Kyo Chung.   

Abstract

BACKGROUND: To evaluate the diagnostic accuracy of (18)F-FDG PET/CT in detection of recurrent differentiated thyroid cancer (DTC) in patients with elevated stimulated thyroglobulin (Tg) or anti-Tg antibody (Ab) levels, and negative (131)I whole body scan according to the Tg level.
METHODS: PET/CT images of well DTC patients who had total thyroidectomy and radioiodine ablation were included. Patients showing elevated Tg titer (≥2.0 ng/ml after TSH stimulation) or elevated anti-Tg titer (≥70.0 IU/ml) while diagnostic radioiodine scan was negative were enrolled. PET/CT was classified as positive or negative on the basis of visual interpretation. The maximum standard uptake values (SUVmax) of the suspected lesions on PET/CT were also recorded. The PET/CT findings were compared with histological or clinical follow-up results based on other imaging modalities and serum Tg/anti-Tg Ab titers. The diagnostic performance of PET/CT was compared among 4 subgroups according to the Tg level [2 ng/ml ≤ stimulated Tg (sTg) < 5 ng/ml, 5 ng/ml ≤ sTg < 10 ng/ml, 10 ng/ml ≤ sTg < 20 ng/ml, and ≥20 ng/ml].
RESULTS: A total of 68 PET/CT images from 60 patients were included, and histological confirmations were available in 32 images. The sensitivity, specificity, accuracy, positive predictive value and negative predictive value of PET/CT were 69.4, 66.7, 69.1, 95.6, and 17.4%, respectively. There were 3 PET/CT cases with high anti-Tg Ab level, and low (<2 ng/ml) Tg level, and all 3 were positive of recurrence. The mean SUVmax of the suspected lesions on PET/CT was 2.9 ± 4.5 (range 1.3-29.7). The sensitivity of PET/CT according to Tg levels was 28.6% when Tg was between 2 and 5, 57.1% between 5 and 10, 60.0% between 10 and 20, and 85.7% when Tg was equal to or greater than 20 ng/ml sub-groups, respectively.
CONCLUSION: Diagnostic accuracy of FDG PET in radioiodine negative thyroid cancer may vary depending on serum Tg levels at imaging. (18)F-FDG PET/CT is useful in detection and localization of recurrent thyroid cancer in patients with negative diagnostic radioiodine scan despite elevated Tg greater than 20 ng/ml or high anti-Tg Ab titers. In contrast, PET/CT provides little additional information when the Tg is less than 5 ng/ml.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21971605     DOI: 10.1007/s12149-011-0536-5

Source DB:  PubMed          Journal:  Ann Nucl Med        ISSN: 0914-7187            Impact factor:   2.668


  11 in total

1.  Therapeutic impact of (18)F-FDG PET/CT in recurrent differentiated thyroid carcinoma.

Authors:  Fabio Pomerri; Anna Rita Cervino; Faise Al Bunni; Laura Evangelista; Pier Carlo Muzzio
Journal:  Radiol Med       Date:  2013-11-26       Impact factor: 3.469

2.  Optimal threshold of stimulated serum thyroglobulin level for 18F-FDG PET/CT imaging in patients with thyroid cancer.

Authors:  Hong Chai; Hu Zhang; Yong-Li Yu; Yun-Chao Gao
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2017-06-06

3.  The Utility of 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Differentiated Thyroid Cancer Patients with Biochemical Recurrence and Negative Whole-Body Radioiodine Scintigraphy and Evaluation of the Possible Role of a Limited Regional Scan.

Authors:  Manish Ora; Aftab Hasan Nazar; Prasanta Kumar Pradhan; Prabhakar Mishra; Sukanta Barai; Amitabh Arya; Manish Dixit; Ashutosh Parashar; Sanjay Gambhir
Journal:  Indian J Nucl Med       Date:  2020-07-01

4.  Molecular Testing for Oncogenic Gene Alterations in Pediatric Thyroid Lesions.

Authors:  Sogol Mostoufi-Moab; Emmanuel Labourier; Lisa Sullivan; Virginia LiVolsi; Yimei Li; Rui Xiao; Sylvie Beaudenon-Huibregtse; Ken Kazahaya; N Scott Adzick; Zubair Baloch; Andrew J Bauer
Journal:  Thyroid       Date:  2017-12-11       Impact factor: 6.568

5.  Value of Dedicated Head and Neck 18F-FDG PET/CT Protocol in Detecting Recurrent and Metastatic Lesions in Post-surgical Differentiated Thyroid Carcinoma Patients with High Serum Thyroglobulin Level and Negative 131I Whole-body Scan.

Authors:  Mai Hong Son; Bui Quang Bieu; Le Ngoc Ha
Journal:  Asia Ocean J Nucl Med Biol       Date:  2016

6.  F18-FDG-PET for recurrent differentiated thyroid cancer: a systematic meta-analysis.

Authors:  Torjan Haslerud; Katrin Brauckhoff; Lars Reisæter; Regina Küfner Lein; Achim Heinecke; Jan Erik Varhaug; Martin Biermann
Journal:  Acta Radiol       Date:  2015-07-09       Impact factor: 1.990

7.  Diagnostic Performance of 18F-FDG PET/CT in Papillary Thyroid Carcinoma with Negative 131I-WBS at first Postablation, Negative Tg and Progressively Increased TgAb Level.

Authors:  Zhong-Ling Qiu; Wei-Jun Wei; Chen-Tian Shen; Hong-Jun Song; Xin-Yun Zhang; Zhen-Kui Sun; Quan-Yong Luo
Journal:  Sci Rep       Date:  2017-06-06       Impact factor: 4.379

8.  2-[18F]FDG PET in the Management of Radioiodine Refractory Differentiated Thyroid Cancer in the Era of Thyrosin-Kinases Inhibitors: A Real-Life Retrospective Study.

Authors:  Stefano Gay; Stefano Raffa; Anna De'Luca di Pietralata; Matteo Bauckneht; Lara Vera; Alberto Miceli; Manuela Albertelli; Silvia Morbelli; Massimo Giusti; Diego Ferone
Journal:  Diagnostics (Basel)       Date:  2022-02-16

9.  Head-to-head comparison of F-18 FDG PET/CT in radioidine refractory thyroid cancer patients with elevated versus suppressed TSH levels a pilot study.

Authors:  Ludmila Santiago Almeida; Maidane Luisi Araújo; Allan Oliveira Santos; Lígia Vera Montali da Assumpção; Mariana Lopes Lima; Celso Darío Ramos; Denise Engelbrecht Zantut-Wittmann; Elba Cristina Etchebehere
Journal:  Heliyon       Date:  2020-03-05

10.  A Stepwise Approach Using Metastatic Lymph Node Ratio-Combined Thyroglobulin for Customization of [18F]FDG-PET/CT Indication to Detect Persistent Disease in Patients with Papillary Thyroid Cancer.

Authors:  Hong Hua Piao; Subin Jeon; Su Woong Yoo; Young Jae Ryu; Dong-Yeon Kim; Ayoung Pyo; Hee-Seung Bom; Jung-Joon Min; Seong Young Kwon
Journal:  Diagnostics (Basel)       Date:  2021-05-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.